1. Home
  2. companies
  3. Benlysta

Benlysta

AstraZeneca lupus drug produces positive results in trial
AstraZeneca lupus drug produces positive results in trial
Yahoo/Reuters
AstraZeneca
lupus
Benlysta
sifalimumab
GlaxoSmithKline Launches Phase 3 Trial for Benlysta
GlaxoSmithKline Launches Phase 3 Trial for Benlysta
Motley Fool
GSK
Benlysta
ANCA-positive vasculitis
10 top drug launch disasters
10 top drug launch disasters
Fierce Pharma
drug launches
Rare Disease Therapeutics
Anascorp
AstraZeneca
Brilinta
Somaxon
Silenor
Sanofi
Multaq
Savient
Krystexxa
XenoPort
Horizant
Human Genome Sciences
Benlysta
Zaltrap
Dendreon
Provenge
KV Pharmaceutical
Makena
Biogen Sells Benlysta Rights
Biogen Sells Benlysta Rights
Yahoo/Zacks
Biogen
Benlysta
GSK
3 Things to Watch With Human Genome Sciences
3 Things to Watch With Human Genome Sciences
Motley Fool
Human Genome Sciences
M&A
Benlysta
Lower Price of Benlysta Could Boost HGSI
Lower Price of Benlysta Could Boost HGSI
Motley Fool
Benlysta
Human Genome Sciences
GSK
lupus
Will Human Genome End Up Blazing A Trail For Others?
Will Human Genome End Up Blazing A Trail For Others?
Seeking Alpha
Human Genome Sciences
GSK
Eli Lilly
Benlysta
Anthera
Immunomedics
lupus
Human Genome jumps 12% in midday trading
Human Genome jumps 12% in midday trading
Marketwatch
Human Genome Sciences
Benlysta
A Bad Year for the 6,300% Miracle (Human Genome Sciences)
A Bad Year for the 6,300% Miracle (Human Genome Sciences)
Motley Fool
Human Genome Sciences
Benlysta
lupus
GSK
Human Genome Bungles Benlysta
Human Genome Bungles Benlysta
TheStreet.com
Human Genome Sciences
Benlysta
lupus
Dated Information Causes Human Genome To Pop
Dated Information Causes Human Genome To Pop
Seeking Alpha
Human Genome Sciences
GSK
M&A
Benlysta
Merck
Biogen Idec
We Don't Care if It's the First Lupus Drug in 50 Years (in UK)
We Don't Care if It's the First Lupus Drug in 50 Years (in UK)
Motley Fool
lupus
Benlysta
Human Genome Sciences
GSK
Human Genome slides on U.K. setback
Human Genome slides on U.K. setback
MarketWatch
Human Genome Sciences
lupus
Benlysta
Human Genome Sciences stock falls as Britain denies funding for Benlysta
Human Genome Sciences stock falls as Britain denies funding for Benlysta
Bizjournals.com
Human Genome Sciences
UK
Benlysta
lupus
GSK
Human Genome Spikes On Sales: Good Time To Consider Buying
Human Genome Spikes On Sales: Good Time To Consider Buying
Seeking Alpha
Human Genome Sciences
GSK
Benlysta
lupus
Human Genome rallies 12% on lupus drug sales
Human Genome rallies 12% on lupus drug sales
Marketwatch
Human Genome Sciences
Benlysta
lupus
Analyst says Human Genome's lupus treatment Benlysta receiving lukewarm reception from doctors
Analyst says Human Genome's lupus treatment Benlysta receiving lukewarm reception from doctors
Yahoo/AP
lupus
Benlysta
Human Genome Sciences
Human Genome Sciences: Slow Benlysta Launch Results In Good Short Candidate
Human Genome Sciences: Slow Benlysta Launch Results In Good Short Candidate
Seeking Alpha
Benlysta
Human Genome Sciences
lupus
GSK
Human Genome: $7.8M in Lupus Drug Sales
Human Genome: $7.8M in Lupus Drug Sales
TheStreet.com
Human Genome Sciences
lupus
GSK
Benlysta
5 Biotech Drug-Launch Stocks to Watch
5 Biotech Drug-Launch Stocks to Watch
TheStreet.com
Human Genome Sciences
Vertex Pharmaceuticals
Acorda Therapeutics
Dendreon
Avanir
lupus
Benlysta
Incivek
hepatitis C
MS
AMPYRA
Provenge
prostate cancer
Nuedexta
PBA

Click here to subscribe to daily news headlines in your email inbox